148 related articles for article (PubMed ID: 18247403)
21. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
[TBL] [Abstract][Full Text] [Related]
22. The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models.
Evans S; Dizeyi N; Abrahamsson PA; Persson J
Anticancer Res; 2009 Oct; 29(10):3917-24. PubMed ID: 19846929
[TBL] [Abstract][Full Text] [Related]
23. Potent oncolytic activity of human enteroviruses against human prostate cancer.
Berry LJ; Au GG; Barry RD; Shafren DR
Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
[TBL] [Abstract][Full Text] [Related]
24. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
[TBL] [Abstract][Full Text] [Related]
25. Noscapine inhibits human prostate cancer progression and metastasis in a mouse model.
Barken I; Geller J; Rogosnitzky M
Anticancer Res; 2008; 28(6A):3701-4. PubMed ID: 19189652
[TBL] [Abstract][Full Text] [Related]
26. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
27. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
28. Systemic administration of hemoglobin vesicle elevates tumor tissue oxygen tension and modifies tumor response to irradiation.
Yamamoto M; Izumi Y; Horinouchi H; Teramura Y; Sakai H; Kohno M; Watanabe M; Kawamura M; Adachi T; Ikeda E; Takeoka S; Tsuchida E; Kobayashi K
J Surg Res; 2009 Jan; 151(1):48-54. PubMed ID: 18262559
[TBL] [Abstract][Full Text] [Related]
29. [Prostatic epidermoid carcinoma: report of a new case an review of the literature].
Mayayo Vicente MS; Fernández Arjona M; Gascón Veguín JP; Jiménez Sánchez F; Puig Rullan AM; Cortés Aránguéz I
Arch Esp Urol; 2003 Oct; 56(8):939-43. PubMed ID: 14639850
[TBL] [Abstract][Full Text] [Related]
30. Marked inhibition of growth and invasive parameters of head and neck squamous carcinoma FaDu by a nutrient mixture.
Roomi MW; Roomi NW; Kalinovsky T; Rath M; Niedzwiecki A
Integr Cancer Ther; 2009 Jun; 8(2):168-76. PubMed ID: 19679626
[TBL] [Abstract][Full Text] [Related]
31. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides.
Makovitzki A; Fink A; Shai Y
Cancer Res; 2009 Apr; 69(8):3458-63. PubMed ID: 19351852
[TBL] [Abstract][Full Text] [Related]
32. Dietary genistein inhibits metastasis of human prostate cancer in mice.
Lakshman M; Xu L; Ananthanarayanan V; Cooper J; Takimoto CH; Helenowski I; Pelling JC; Bergan RC
Cancer Res; 2008 Mar; 68(6):2024-32. PubMed ID: 18339885
[TBL] [Abstract][Full Text] [Related]
33. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
34. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
35. A novel method of generating prostate cancer metastases from orthotopic implants.
Corey E; Quinn JE; Vessella RL
Prostate; 2003 Jul; 56(2):110-4. PubMed ID: 12746835
[TBL] [Abstract][Full Text] [Related]
36. Particle irradiation suppresses metastatic potential of cancer cells.
Ogata T; Teshima T; Kagawa K; Hishikawa Y; Takahashi Y; Kawaguchi A; Suzumoto Y; Nojima K; Furusawa Y; Matsuura N
Cancer Res; 2005 Jan; 65(1):113-20. PubMed ID: 15665286
[TBL] [Abstract][Full Text] [Related]
37. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
38. Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma.
Angelucci A; Muzi P; Cristiano L; Millimaggi D; Cimini A; Dolo V; Miano R; Vicentini C; Cerù MP; Bologna M
Prostate; 2008 May; 68(6):588-98. PubMed ID: 18288684
[TBL] [Abstract][Full Text] [Related]
39. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
Russell MR; Jamieson WL; Dolloff NG; Fatatis A
Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
[TBL] [Abstract][Full Text] [Related]
40. [Small cell carcinoma of the prostate: a case report].
Yamamoto N; Kinoshita H; Inoue T; Kawakita S; Oguchi N; Muguruma K; Kawa G; Sakaguchi Y; Adachi Y; Sakaida N; Uemura Y; Matsuda T
Hinyokika Kiyo; 2007 Sep; 53(9):665-9. PubMed ID: 17933147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
